A study assessing the outcome of immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC)
Latest Information Update: 26 Mar 2020
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Mar 2020 New trial record
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium